A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy
2026년 6월 12일 업데이트: Kerri Winters, OHSU Knight Cancer Institute
Community for Physical Activity and Supportive Nutrition Strategies (COMPASS)
This clinical trial studies whether a tailored, web-based program (web portal), Community for Physical Activity and Supportive Nutrition Strategies (COMPASS), can be used to improve exercise and dietary changes in patients with stage I-III pancreatic cancer who are receiving chemotherapy before surgery (neoadjuvant).
Pancreatic cancer is a rare and understudied cancer, particularly in the area of promoting a healthy lifestyle to preserve physical and mental well-being during a long and difficult treatment regimen.
Since pancreatic cancer is rare, programs have limited resources available to reach the patients who could benefit from programs aimed at promoting exercise and a healthy diet.
The COMPASS web-portal is easily accessed by the patient via a computer, tablet, or phone.
It is tailored to the unique needs of pancreatic cancer patients and provides exercise and diet recommendations along with behavioral support as they undergo the long process of cancer therapy.
This may be a more effective way to reach and engage with the patient, which may improve exercise and dietary changes in stage I-III pancreatic cancer patients receiving neoadjuvant chemotherapy.
연구 개요
상태
모병
상세 설명
PRIMARY OBJECTIVE:
I. Acceptability of the COMPASS web portal will be assessed through accrual, study retention, end-of-study focus groups, and exit surveys, while feasibility will be measured by adherence to prescribed recommendations, frequency of portal visits, and aggregate web portal usage data.
SECONDARY OBJECTIVE:
I. To evaluate the preliminary effectiveness of COMPASS on exercise and diet habits, self-efficacy for behavior change, stages of change for exercise, changes in physical and mental well-being, and treatment tolerance (treatment-related symptoms, side effects, # of dose reductions) at baseline, 3 months and post chemotherapy.
TERTIARY OBJECTIVE:
I. To compare outcomes between participants assigned to a single health coaching session or monthly coaching sessions.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP 1: Patients receive access to COMPASS portal, a tailored exercise intervention which may consist of strength, aerobic, balance, and flexibility exercises, and tailored diet recommendations for the duration of neoadjuvant chemotherapy. Patients also attend two review sessions to discuss the tailored exercise intervention and dietary recommendations and may optionally receive motivational and support text messages three times a week (TIW) on study.
GROUP 2: Patients receive access to COMPASS portal, a tailored exercise intervention which may consist of strength, aerobic, balance, and flexibility exercises, and tailored diet recommendations for the duration of neoadjuvant chemotherapy. Patients also attend two review sessions to discuss the tailored exercise intervention and dietary recommendations and receive a coaching call once a month on study. Additionally, patients may optionally receive motivational and support text messages TIW on study.
연구 유형
중재적
등록 (추정된)
30
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- 모병
- OHSU Knight Cancer Institute
-
연락하다:
- Kerri Winters-Stone
- 전화번호: 503-494-0813
- 이메일: wintersk@ohsu.edu
-
수석 연구원:
- Kerri Winters-Stone
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
Age 18 years or older on date of enrollment
- Confirmed by review of the date of birth as documented in the electronic medical record (EMR) and subsequently recorded in a case report form (CRF)
Diagnosed with stage I-III pancreatic cancer
- Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm
Scheduled to receive neoadjuvant chemotherapy at Oregon Health & Science University (OHSU)
- Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm
Willing to adhere to the study protocol
- Confirmed verbally with the participant and response documented in the Participant Tracking database
Exclusion Criteria:
Cognitive difficulties that preclude answering the survey questions, participating in the intervention, or giving informed consent
- In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the Principal Investigators, Dr. Kerri Winters-Stone and/or Dr. Jackilen Shannon
A medical condition, movement or neurological disorder, or medication use that contraindicates participation in light intensity exercise
- Confirmed by a combination of reviewing the EMR, and self-report during the initial screening call. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone or Dr. Jackilen Shannon, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible
Not fluent in English and therefore incapable of answer survey questions, reading the intervention web portal, and providing informed consent in English
- Confirmed verbally with the participant and response documented in the Participant Tracking database
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Group 1 (COMPASS + brief coaching support)
Participants receive access to COMPASS portal, a tailored exercise intervention which may consist of strength, aerobic, balance, and flexibility exercises, and tailored diet recommendations for the duration of neoadjuvant chemotherapy.
Participants also receive an initial coaching call to discuss the tailored exercise intervention and dietary recommendations and may optionally receive motivational and support text messages TIW on study.
|
Web-based lifestyle program that provides tailored nutrition and physical activity recommendations and web-based support strategies including text messages, electronic trackers, and coaching
|
|
실험적: Group 2 (COMPASS + enhanced coaching support)
Participants receive the same intervention as Group 1, but receive additional monthly coaching support
|
Web-based lifestyle program that provides tailored nutrition and physical activity recommendations and web-based support strategies including text messages, electronic trackers, and coaching
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Accrual (Acceptability)
기간: Up to 12 months
|
Accrual will be measured by the number of eligible patients who enroll in the study divided by the total number approached for recruitment.
Successful accrual will be defined as recruiting 30 pancreatic cancer patients
|
Up to 12 months
|
|
Study retention (Acceptability)
기간: Up to 12 months
|
Measured by the number of participants who enroll and complete the study intervention during their neoadjuvant chemotherapy treatment.
Successful retention will be if 80% (24) participants complete the study's intervention while in neoadjuvant chemotherapy.
|
Up to 12 months
|
|
Listening session
기간: At completion of neoadjuvant chemotherapy (average of 6 months)
|
A minimum of 2 and maximum of 4 virtual listening sessions, at least one of men and one of women will be conducted.
Each group will consist of 8-10 individuals and will explore questions of ease of use, whether they felt the portal was engaging and effectively encouraged positive behaviors.
Information will also be sought about how the portal may be improved.
|
At completion of neoadjuvant chemotherapy (average of 6 months)
|
|
Exit survey
기간: At completion of neoadjuvant chemotherapy (average of 6 months)
|
This survey will assess which parts of the web portal and intervention participants felt were most useful.
The survey includes questions about each component of the web portal and intervention, with responses ranging from "Strongly Disagree" to "Strongly Agree," as well as open-ended questions that allow participants to provide additional thoughts or comments about the web portal.
|
At completion of neoadjuvant chemotherapy (average of 6 months)
|
|
Study intervention adherence (Feasibility)
기간: Up to 12 months
|
Adherence will be defined as the proportion of participants who achieve at least one prescribed weekly exercise goal or nutrition recommendation during ≥80% of the weeks of their neoadjuvant chemotherapy period.
Values range from 0% to 100%, with higher percentages indicating greater adherence to the study intervention.
|
Up to 12 months
|
|
Web portal visit frequency (Feasibility)
기간: Up to 12 months
|
Will be measured by the number of times participants logged into the web portal during the intervention period.
|
Up to 12 months
|
|
Web portal aggregate activity (Feasibility)
기간: Up to 12 months
|
The number of clicks on specific web portal components, most frequently visited web pages, average time spent on the web portal and on different sections, time spent logging information or syncing Fitbit data
|
Up to 12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in self-report physical activity behavior
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Community Health Activities Model Program physical activity survey as total energy expended in moderate to vigorous physical activity per week (kcal/week)
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in dietary behavior
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Diet Questionnaire for Oncology Participants.
This survey assesses the frequency of consumption of specific foods or food groups (e.g., bread, cereal, milk, fruit juice) and how much of each food they typically eat per week.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in objectively measured physical activity (kcal/week)
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Physical activity will be measured using a Fitbit device for energy expenditure (kcal/week)
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in objectively measured physical activity (daily step count)
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Physical activity will be measured using a Fitbit activity monitor and reported as average daily step count.
Daily step count represents the total number of steps accumulated during a day.
Possible values range from 0 steps to no defined upper limit.
Higher values (average daily steps) indicate greater physical activity.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in Self-efficacy for Exercise score
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be measured using a 6-item measure of Self-efficacy for Exercise.
Summed scores range from 6-30, and higher scores indicate higher self-efficacy
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in stages of change for exercise
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Physical Activity Stage Assessment (PASA) measure.
Participants select one of five statements that best describes their current exercise behavior and readiness to engage in regular physical activity.
Values range from 1 to 5, with higher values indicating greater engagement in and maintenance of regular exercise.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Healthy Eating and Weight Self-Efficacy
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
The Healthy Eating and Weight Self-Efficacy (HEWSE) questionnaire assesses participants' self-efficacy by asking them to rate their confidence in performing various tasks on a 1-5 Likert scale.
A score of 1 indicates strong disagreement with their ability to accomplish the task, while a score of 5 indicates strong agreement.
Higher scores indicate greater self-efficacy for healthy eating and weight management behaviors.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in self-report physical functioning, quality of life, and cancer related symptoms
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
This outcome will assess overall quality of life and cancer-related symptoms.
Scores range from 0 to 100.
For the global health status and functional scales, higher scores indicate better quality of life and functioning.
For symptom scales, higher scores indicate greater symptom burden and worse outcomes.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Symptom Measures
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Participant-Reported Outcomes Measurement Information System (PROMIS) measures for Sleep Disturbance, Depression, Anxiety, and Fatigue.
Participants respond to 8-13 questions regarding their symptoms, with responses ranging from "Not at all" to "Very much."
Scores are converted to standardized T-scores, with higher scores indicating greater symptom severity and worse outcomes.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in cognitive function
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Participant-Reported Outcomes Measurement Information System Cognitive Function (PROMIS-CF) survey.
This 32-item questionnaire assesses perceived difficulties with memory, cognitive processing, and the impact of cognitive problems on daily and social activities.
Scores range from 0 to 100, with higher scores indicating better cognitive function and fewer perceived cognitive difficulties.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in neuropathy
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity 4 (FACT-GOG-NXT-4).
This 4-item survey captures symptoms of peripheral neuropathy, including sensory, motor, and auditory problems and cold sensitivity.
Higher scores indicate more symptoms
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in pain
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Participant-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity and Pain Interference measures.
The Pain Intensity measure assesses the severity of pain, while the Pain Interference measure assesses the extent to which pain affects daily activities, social activities, and overall functioning.
Scores range from 0 to 100, with higher scores indicating greater pain severity and greater interference of pain with daily functioning, representing worse outcomes.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in treatment dosing
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
These data will be available via the electronic health record and may be extracted to explore the impact of COMPASS on clinical outcomes including grade 3+ toxicities, dose delays and dose reductions.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Incidence of adverse events
기간: At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Tolerance and safety will be assessed by adverse event reporting administered monthly by a survey administered by the web portal.
Adverse events will be classified as related, possibly related, or not related to the intervention and graded as mild, moderate or severe.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 수석 연구원: Kerri Winters-Stone, OHSU Knight Cancer Institute
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2026년 4월 15일
기본 완료 (추정된)
2027년 1월 31일
연구 완료 (추정된)
2027년 6월 30일
연구 등록 날짜
최초 제출
2026년 4월 28일
QC 기준을 충족하는 최초 제출
2026년 6월 12일
처음 게시됨 (실제)
2026년 6월 16일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 6월 16일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 6월 12일
마지막으로 확인됨
2026년 6월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
II기 췌장암 AJCC v8에 대한 임상 시험
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
University of UtahNational Cancer Institute (NCI)완전한피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center모병전립선 선암종 | IV기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IIIB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center모병거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center모병전립선 선암종 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IVA기 전립선암 AJCC v8 | IIB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
OHSU Knight Cancer InstituteOregon Health and Science University모집하지 않고 적극적으로췌장 선암종 | III기 췌장암 미국 암 연합 위원회 v8 | 미국암연합위원회 v8 기준 0기 췌장암 | 미국암연합위원회 v8 기준 1기 췌장암 | Stage IV 췌장암 American Joint Committee on Cancer v8미국
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)모집하지 않고 적극적으로임상 3기 위식도 접합부 선암종 AJCC v8 | 임상 II기 식도 선암종 AJCC v8 | 임상 병기 IIA 식도 선암종 AJCC v8 | 임상 3기 식도 선암종 AJCC v8 | 병리학 IB기 식도 선암종 AJCC v8 | 병리학적 병기 IC 식도 선암종 AJCC v8 | 병리학적 병기 II 식도 선암종 AJCC v8 | 병리학적 병기 IIA 식도 선암종 AJCC v8 | 병리학적 병기 IIB 식도 선암종 AJCC v8 | 병리학적 3기 식도 선암종 AJCC v8 | 병리학적 병기 IIIA 식도 선암종 AJCC v8 | 병리학적 병기 IIIB 식도 선암종 AJCC v8 그리고 다른 조건미국
Physical Activity and Nutritional Recommendations and Support에 대한 임상 시험
-
University of OregonSpecial X Inc.완전한부모-자녀 관계 | 육아 | 아동 행동 | 발달 장애 | 개발 지연 | 발달 장애, 아동미국
-
Oregon Health and Science University모집하지 않고 적극적으로상처와 부상 | 통증 관리 | 인간 공학미국
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Splendor-NC완전한비만 | 초과 중량 | 체중 | 체중 감량 | 체중 변화 | 만성 질환 | 과체중 및 비만 | 신체 활동 부족 | 행동, 식사 | 중량 감소미국
-
Université Catholique de LouvainKU Leuven; Epsylon, ASBL아직 모집하지 않음